UroGen Pharma Ltd.
URGN
$29.80
-$1.53-4.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -23.57M | -26.36M | -33.35M | -49.94M | -43.84M |
| Total Depreciation and Amortization | 652.00K | 679.00K | 639.00K | 596.00K | 497.00K |
| Total Amortization of Deferred Charges | -- | -- | -774.00K | 774.00K | -- |
| Total Other Non-Cash Items | 7.69M | 4.42M | 6.06M | 2.90M | 3.91M |
| Change in Net Operating Assets | -30.08M | -17.06M | -14.85M | 5.85M | -2.59M |
| Cash from Operations | -45.32M | -38.33M | -42.27M | -39.83M | -42.02M |
| Capital Expenditure | -54.00K | -17.00K | -87.00K | -141.00K | -44.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -20.63M | 27.73M | 31.49M | 28.55M | -25.92M |
| Cash from Investing | -20.69M | 27.72M | 31.40M | 28.41M | -25.96M |
| Total Debt Issued | 65.35M | -- | -- | -- | -- |
| Total Debt Repaid | -321.00K | -1.86M | -- | -- | -- |
| Issuance of Common Stock | 179.00K | 33.17M | 8.27M | 293.00K | 34.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -3.00K | 0.00 | 3.00K | -- |
| Cash from Financing | 65.20M | 31.32M | 8.27M | 296.00K | 34.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -800.00K | 20.71M | -2.60M | -11.12M | -67.95M |